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The ancient paradigm that one microorganism causes one
infection that has become entrenched within our fundamental
understanding of microbiology since the time of Robert Koch
is now being repeatedly challenged. For well over a decade
now, this dogma has been contested, with expansion in our
conceptualization of how microorganisms multiply in situ,
often growing in bioﬁlms rather than in the planktonic cultures
with which we make our laboratory predictions on how these
organisms might respond to various therapeutic interventions.
These are often not growing as a pure culture, but instead
employ variegated interactions between both similar and
unrelated microorganisms within this diverse heterogeneous
population. The review by Wolcott and Costerton provides a
valuable overview of our current understanding of these
polymicrobial communities that has helped our understanding
of the challenges of managing infections, particularly those
associated with indwelling devices and complex microbial
communities [1]. The application of metagenomic approaches
has helped us to unravel some of the intricacies by which these
communities recruit further microorganisms and work collec-
tively, utilizing a ‘distributive genome’ to provide a recalcitrant
population resistant to their surrounding forces [1]. Appreci-
ation of these polymicrobial communities and their enhanced
abilities to persist, withstanding both host immune interven-
tions and therapeutic strategies, will improve our appreciation
of these communities and evaluation of innovative intervention
strategies. We are further indebted to the contributions of Bill
Costerton, who sadly passed away during the ﬁnal stages of
the preparation of this review.
Although microbial superinfections have been recognized
since the early 19th century, the multiplicity of factors that
exacerbate their development remain poorly understood. The
review by Jon McCullers opens up another dimension of the
consequences of multiple infections. Within this thought-
provoking review, he debates the clinical outcome following
infection with inﬂuenza virus, comparing and contrasting the
potential for secondary bacterial infections with pandemic
strains that are newly associated with their human hosts, as
compared with seasonal strains that have become adapted to
infection of their human hosts [2]. Within his review, he
highlights the limitation of our current data capture that makes
it impossible to disentangle those cases resulting from
pandemic and from seasonal strains. Without this level of
detail, giving both typing information and geographical data, it is
impossible to draw more detailed conclusions regarding strain
type and location, and their propensity to predispose individ-
uals to greater risk of secondary infections, increasing the
severity following this scenario. Further limitations arise from
the capture of mortality statistics as compared with the
probably greater burden of non-lethal infections that, in many
cases, are not reported [2]. This review offers many as yet
poorly investigated possibilities of how one infection might
inﬂuence the potential for succumbing to another, with
particularly severe adverse outcomes for the human host.
One such example is the apparent correlation of viral
neuraminidase activity and the likelihood of succumbing to
secondary bacterial infection [2].
Our appreciation of microbial interactions is further
emerging beyond the above interactions between separate
entities such as those seen within bioﬁlms and co-infections,
with a growing realization that organisms themselves can be
infected with other agents that might inﬂuence their virulence,
longevity, nutritional capabilities, or response to potential
intervention strategies. Some Leishmania parasites also harbour
a cytoplasmic RNA virus (Leishmania RNA virus) that can
inﬂuence the upregulation of inﬂammatory cascades and thus
impact on the pathological consequences of infection [3].
Unsurprisingly, co-infection with human immunodeﬁciency
virus enhances the susceptibility to leishmaniasis by 1000-fold,
which, coupled with the bias towards a Th2 response, has
severe consequences for disease progression [3]. This has
resulted in an upsurge of complicated atypical infections that
are challenging to manage with currently available arsenals.
Potential targets to tip the balance in favour of the human host
to control and eventually eliminate these parasites are
excellently reviewed by Hartley and coworkers, who highlight
the need to tailor the immunomodulatory therapeutic regimes
appropriately to the type of leishmaniasis [3].
The last of our reviews is focused on intrinsic ‘nested’ co-
infections, such as the Leishmania RNA virus example above,
namely the ﬁnding that signiﬁcant proportions of the Onchoc-
ercidae are themselves infected with Wolbachia species. Mem-
bers of the Onchocercidae family include the cause of notable
humanﬁlarial infections, such as lymphatic ﬁlariasis (elephantiasis)
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and onchocerciasis (river blindness). Collectively, these infec-
tions afﬂict up to 180 million people residing within endemic
zones [4]. The impact of these infections extends beyond human
infection to include a range of infections of veterinary importance
among both livestock and companion animals. With the excep-
tion of the ﬁlariae causing Loa loa ﬁlariasis, those that infect
humans are all themselves harbouringWolbachia. This apparently
synergistic arrangement enables enhanced establishment of the
ﬁlariaewithin their humanhost through theability ofWolbachia to
exacerbate the proinﬂammatory response, thus helping the
nematodes to successfully reach their target locations. Further-
more, the presence of Wolbachia is correlated with recruitment
of neutrophils rather than a ﬁlaricidal eosinophilic host response,
soWolbachia appears to enhance the survival of these nematodes
within the human host [4]. The inappropriate neutrophil
response has been associated with subsequent pathology of
corneal inﬂammation in cases of onchocerciasis [4].
This synergistic union between multiple pathogens opens
potential new therapeutic options that target one member of
this union, thus tipping the balance towards the demise of its
‘partner in crime’. Indeed, doxycycline has been used in this
way for the management of both lymphatic ﬁlariasis and
onchocerciasis. Novel therapeutic agents, such as corallopy-
ronin A and berberin, are both under evaluation for their
ability to inhibit RNA synthesis and cytokinesis, respectively,
of Wolbachia (reviewed by Bouchery et al. [4]). The com-
plexity of interactions of these parasites extends beyond
those associated with Wolbachia alone, and involves dynamic
interactions with the host’s innate and adaptive immune
responses.
Collectively, these reviews underscore our need to adopt a
more holistic approach to our consideration of infection,
incorporating the role of both extrinsic and intrinsic co-
infections that can modulate, and indeed inﬂuence, the
immunological cross-talk with the immune system of the host.
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